Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Income from Continuing Operations: 2019-2024

Historic Income from Continuing Operations for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to -$235.8 million.

  • Centessa Pharmaceuticals' Income from Continuing Operations fell 28.96% to -$54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.7 million, marking a year-over-year decrease of 50.50%. This contributed to the annual value of -$235.8 million for FY2024, which is 56.04% down from last year.
  • Centessa Pharmaceuticals' Income from Continuing Operations amounted to -$235.8 million in FY2024, which was down 56.04% from -$151.1 million recorded in FY2023.
  • Over the past 5 years, Centessa Pharmaceuticals' Income from Continuing Operations peaked at -$10.7 million during FY2020, and registered a low of -$381.1 million during FY2021.
  • Its 3-year average for Income from Continuing Operations is -$201.0 million, with a median of -$216.2 million in 2022.
  • In the last 5 years, Centessa Pharmaceuticals' Income from Continuing Operations plummeted by 3,473.77% in 2021 and then soared by 43.26% in 2022.
  • Centessa Pharmaceuticals' Income from Continuing Operations (Yearly) stood at -$10.7 million in 2020, then plummeted by 3,473.77% to -$381.1 million in 2021, then surged by 43.26% to -$216.2 million in 2022, then spiked by 30.12% to -$151.1 million in 2023, then tumbled by 56.04% to -$235.8 million in 2024.